KalVista Pharmaceuticals Competitors and Similar CompaniesClear all
KalVista Pharmaceuticals's competitors and similar companies include Orgenesis, Intelligent Bio Solutions, Avid Radiopharmaceuticals and American Hospital.
 KalVista Pharmaceuticals KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME). |  Orgenesis Orgenesis focuses on a novel therapeutic treatment for diabetes by correcting malfunctioning organs with new functional tissues. |  Intelligent Bio Solutions GBS (formerly known as Glucose Biosensor Systems (Greater China) Holdings) is a biosensor diagnostic technology company. |  Avid Radiopharmaceuticals Avid Radiopharmaceuticals is a company developing molecular imaging agents for chronic human diseases. | ||
Founding Date | Founding Date 2011 | Founding Date 2008 | Founding Date N/A | Founding Date 2005 | Founding Date 1996 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Subsidiary |
Tags | |||||
Locations | Locations Porton Down, GB HQ Cambridge, US | Locations Germantown, US HQ Aye, BE Ness Ziona, IL Suwon Si, KR | Locations New York, US HQ Barangaroo, AU | Locations Philadelphia, US HQ | Locations Dubai, AE HQ |
Employees | Employees 150 | Employees 524% decrease | Employees 1623% increase | Employees 933% decrease | Employees 3,6641% increase |
Valuation ($) | Valuation ($) 523.4 m | Valuation ($) N/A | Valuation ($) 7 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $49.1m (FY, 2025) | Revenue (est.) $1m (FY, 2024) | Revenue (est.) $3.1m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $3.1m (FY, 2025) | Cost of goods $1.9m (FY, 2024) | Cost of goods $1.8m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $46m (FY, 2025) | Gross profit ($893k) (FY, 2024) | Gross profit $1.2m (FY, 2025) | Gross profit N/A | Gross profit N/A |
Net income | Net income ($109.5m) (FY, 2025) | Net income N/A | Net income ($10.6m) (FY, 2025) | Net income N/A | Net income N/A |
For sources of this data, please see the company profile
View Company Profiles
Orgenesis
HQ
Germantown, US
Employees
52↓ 4% decrease
Orgenesis focuses on a novel therapeutic treatment for diabetes by correcting malfunctioning organs with new functional tissues.
View companyIntelligent Bio Solutions
HQ
New York, US
Employees
16↑ 23% increase
GBS (formerly known as Glucose Biosensor Systems (Greater China) Holdings) is a biosensor diagnostic technology company.
View companyAvid Radiopharmaceuticals
HQ
Philadelphia, US
Avid Radiopharmaceuticals is a company developing molecular imaging agents for chronic human diseases.
View company